Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ACKR3 | P25106 | 15/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24124166 | 0.82 | HDAC8 (0.48) | RAB9AGAAHTTACKR3KDM4E | |
| SCHEMBL24124212 | 0.80 | MAPT (0.61) | RAB9AGAAHTTKDM4EALDH1A1 | |
| SCHEMBL24124243 | 0.79 | NPC1 (0.50) | RAB9AGAAHTTKDM4EALDH1A1 | |
| SCHEMBL24124799 | 0.79 | MAPT (0.60) | RAB9AGAAHTTKDM4EALDH1A1 | |
| SCHEMBL24124181 | 0.79 | PTGES (0.44) | RAB9AACKR3KDM4EALDH1A1MAPT | |
| SCHEMBL24125238 | 0.78 | NPC1 (0.43) | RAB9AACKR3KDM4EMAPT | |
| SCHEMBL27101124 | 0.76 | ACKR3 (0.60) | USP7RAB9AGAAHTTACKR3 | |
| SCHEMBL25921185 | 0.75 | MAPT (0.46) | RAB9AGAAHTTKDM4EALDH1A1 | |
| SCHEMBL17270179 | 0.74 | ACKR3 (0.74) | USP7RAB9AHTTACKR3KDM4E | |
| SCHEMBL2461162 | 0.74 | USP7 (0.62) | USP7RAB9AGAAHTTACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | USP7 1200/4885RAB9A 1163/4885GAA 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.